A Phase 2 interventional study of VentaProst in Pulmonary Hypertension, sponsored by Aerogen Pharma Limited. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Aerogen Pharma Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 186th largest by enrollment of the 286 interventional ones that give a count, is one of 20 that started in 2017, is one of 93 in phase 2, and was the 241st registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of California, Davis · Sites in United States
Ages up to 28 days
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States
Ages 18+
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 114 · Phase 3 75 · Phase 4 38
First in 1992; this study’s year is marked. 20 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 286 interventional studies, 108 across the 107 observational. Of the 274 that completed or were terminated, 139 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 397 have an industry lead sponsor. The 10 most frequent:
Aerogen Pharma Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Aerogen Pharma Limited has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
21 of the studies in Hypertension, Pulmonary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT05442671Children's Hospital of PhiladelphiaiTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | 2026-12-31 |
| NCT04808596University of Kansas Medical CenterPulmonary Hypertension Biorepository and Registry | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2) demonstrate that an optimum effect can be rapidly obtained with VentaProst titration.
Part I:
This part of the study is designed to demonstrate the dose equivalence between off-label aerosolized epoprostenol and VentaProst using a patient's hemodynamic parameters.
Part II:
This part of the study is designed to establish a dose response relationship of VentaProst to hemodynamic effect by dose escalation in patients who have had cardiac surgery with CPB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients in Part I:
For patients in Part II:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VentaProst (epoprostenol solution for inhalation via custom drug delivery system) In Part 1, subjects were treated with a commercial aerosolized epoprostenol and then removed from that treatment. VentaProst was started and titrated to a dose equivalence to maintain at least 90% of hemodynamic response seen with the commerical product. In Part 2, subjects were treated with VentaProst only.
Combination Product: VentaProst
epoprostenol for inhalation via custom drug delivery system
Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I)
The primary goal was to establish the dose of VentaProst necessary to achieve a PD response comparable to the standard of care. The first dose of VentaProst tested, 17 ng/kg/min, achieved the dose equivalency.
Time frame: Pharmacodynamic changes will be measured during surgery (Day 1), post-surgery (Day 1), and from start of study treatment (Day 1) through study completion (up to 30 days)
Optimal Dose Determination With VP Dose Escalation (Part II)
Calculate vascular resistance indicators for CI and CO, and PAPi at each dose level. Identify the VP dose where mPAP, VR(CO), VR(CI), CVP are lowest, and CI/CO are highest. Compare in a narrative to the selected VP optimal dose by the Investigator by individual patient.
Time frame: Pharmacodynamic changes will be measured during surgery (Day 1), post-surgery (Day 1), and from start of study treatment (Day 1) through study completion (up to 30 days)
| Milestone | VentaProst |
|---|---|
| Started | 9 |
| Completed | 7 |
| Not completed | 2 |
| Milestone | VentaProst |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
The primary goal was to establish the dose of VentaProst necessary to achieve a PD response comparable to the standard of care. The first dose of VentaProst tested, 17 ng/kg/min, achieved the dose equivalency.
| ng/kg/min | VentaProst |
|---|---|
| Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I) | 17 |
Calculate vascular resistance indicators for CI and CO, and PAPi at each dose level. Identify the VP dose where mPAP, VR(CO), VR(CI), CVP are lowest, and CI/CO are highest. Compare in a narrative to the selected VP optimal dose by the Investigator by individual patient.
| ng/kg/min | VentaProst |
|---|---|
| Optimal VP dose 1 | 6.8 |
| Optimal VP dose 2 | 10.2 |
| Optimal VP dose 3 | 13.6 |
Collected over Adverse events were collect from post-cardiac surgery (Day 1) through study completion (up to 30 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Epoprostenol Then VentaProst | 0/7 (0%) | 1/7 (14.3%) | 2/7 (28.6%) |
| Part 2: VentaProst Dose Escalation | 0/8 (0%) | 2/8 (25%) | 1/8 (12.5%) |
| Event | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation |
|---|---|---|
| arterial hemorrhageVascular disorders | 0/7 | 2/8 |
| pulmonary hypertensionCardiac disorders | 1/7 | 0/8 |
| Event | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation |
|---|---|---|
| coagulopathyBlood and lymphatic system disorders | 1/7 | 0/8 |
| adrenal insufficiencyEndocrine disorders | 1/7 | 0/8 |
| acute kidney injuryRenal and urinary disorders | 1/7 | 0/8 |
| acute lung injuryRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 |
| traumatic hemothoraxRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 |
| arterial hemorrhageVascular disorders | 0/7 | 1/8 |
| hemorrhageVascular disorders | 0/7 | 1/8 |
| Age, Continuous(years) | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation | Total |
|---|---|---|---|
| Mean | 66.0 ± 11.47 | 65.6 ± 8.02 | 65.8 ± 9.41 |
| Sex: Female, Male(Participants) | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 6 | 6 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 7 | 14 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 6 | 13 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Weight(Kg) | Part 1: Epoprostenol Then VentaProst | Part 2: VentaProst Dose Escalation | Total |
|---|---|---|---|
| Mean | 85.6 ± 21.11 | 83.6 ± 17.57 | 84.5 ± 18.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Mar 2019, 18 months.
Results were first posted in Jul 2025, 6 years 4 months after primary completion.
Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aerogen Pharma Limited